Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6997956 | 0.86 | ACHE (0.54) | ACHEIDO1TDO2ALDH1A1MAPT | |
| SCHEMBL2064454 | 0.82 | HTT (0.59) | ACHEIDO1TDO2PLAUALDH1A1 | |
| SCHEMBL365917 | 0.82 | ALDH1A1 (0.65) | ACHEIDO1TDO2PLAUALDH1A1 | |
| SCHEMBL4274425 | 0.81 | KDM4E (0.49) | ACHEALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL136101 | 0.81 | MAPT (0.60) | ACHEIDO1TDO2PLAUALDH1A1 | |
| SCHEMBL9277359 | 0.81 | NPC1 (0.64) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL704024 | 0.81 | ACHE (0.57) | ACHEIDO1TDO2PLAUALDH1A1 | |
| SCHEMBL11756782 | 0.81 | ACHE (0.52) | ACHEIDO1TDO2PLAUALDH1A1 | |
| SCHEMBL14038245 | 0.81 | ACHE (0.57) | ACHEIDO1TDO2PLAUALDH1A1 | |
| SCHEMBL11679436 | 0.81 | ACHE (0.52) | ACHEIDO1TDO2PLAUALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0196224-B1 | Synthesis of inotropic imidazo[4,5-c]pyridine | ELI LILLY AND COMPANY (US) | 1989-08-16 | — | — | EP | claimed |
| EP-0196224-A1 | Synthesis of inotropic imidazo[4,5-c]pyridine | ELI LILLY AND COMPANY (US) | 1986-10-01 | — | — | EP | claimed |
| EP-1347963-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| EP-1347963-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-01 | — | — | EP | disclosed |
| US-6433005-B1 | SELECTIVE COX II INHIBITOR | SYNTEX (U.S.A.) LLC | 2002-08-13 | — | — | US | disclosed |
| US-20020107280-A1 | NEW BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | SYNTEX (U.S.A.) LLC | 2002-08-08 | — | — | US | disclosed |
| WO-2002046178-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
| US-5686482-A | DOPAMINE RECEPTOR ANTAGONIST | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0757985-A1 | N-(3-PYRROLIDINYL)BENZAMIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0196224-B1 | Synthesis of inotropic imidazo[4,5-c]pyridine | ELI LILLY AND COMPANY (US) | 1989-08-16 | — | — | EP | disclosed |
| US-4810801-A | Pyrrolobenzimidazoles, pharmaceutical compositions containing them, and use of them to treat certain heart and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1989-03-07 | — | — | US | disclosed |
| US-4710510-A | Pyrrolobenzimidazoles, pharmaceutical compositions containing them, and use of them to treat certain heart and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1987-12-01 | — | — | US | disclosed |
| EP-0196224-A1 | Synthesis of inotropic imidazo[4,5-c]pyridine | ELI LILLY AND COMPANY (US) | 1986-10-01 | — | — | EP | disclosed |
| EP-0196224-A1 | Synthesis of inotropic imidazo[4,5-c]pyridine | ELI LILLY AND COMPANY (US) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107280-A1 | NEW BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | SULT1E1, SULT2A1, SULT1A1 | ACHE 1641/4885IDO1 416/4885TDO2 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.